HaloVax

HaloVax

HaloVax is a special purpose subsidiary of Voltron Therapeutics which reached an agreement with Hoth Therapeutics to co-develop a SARS-CoV-2 vaccine using Voltron's self-assembling vaccine technology.

HaloVax is a special purpose subsidiary of Voltron Therapeutics which reached an agreement with Hoth Therapeutics to co-develop a SARS-CoV-2 vaccine using Voltron's self-assembling vaccine technology.

The mission of HaloVax is to develop a novel, Self-Assembling Vaccine against COVID-19, utilizing technology licensed by Voltron Therapeutics, Inc. from the Vaccine and Immunotherapeutics Center at the Massachusetts General Hospital. The vaccine is being designed from a validated platform to provide customized cellular immunity against COVID-19, as well as be able to adapt rapidly to potential genetic drift of the virus.

Technology

The company was set up to apply Voltron Therapeutics's proprietary self-assembling vaccine (SAV) platform to develop a vaccine for SARS-CoV-2, the virus which causes COVID-19. The technology was developed out of Massachusetts General Hospital and was exclusively licensed to Voltron.

Timeline

March 27, 2020
HaloVax™ Announces Agreement with Hoth Therapeutics to Joint Develop a Self-Assembling Vaccine (SAV) to Protect Patients at Risk of Coronavirus (COVID-19) Infection

HaloVax, LLC a biopharmaceutical company and special purpose subsidiary of Voltron Therapeutics, Inc., announced they have reached an agreement with Hoth Therapeutics, Inc (NASDAQ: HOTH) (previously released) to advance an application of VaxCelerate, a self-assembling vaccine (SAV) platform licensed from the Vaccine and Immunotherapy Center (VIC) at Massachusetts General Hospital (MGH), to develop a vaccine designed to protect patients at risk of Coronavirus (COVID-19) infection.

Voltron Therapeutics, Inc. has acquired an exclusive license to this technology.

People

Name
Role
LinkedIn

Further reading

Title
Author
Link
Type
Date

About

Web

Documentaries, videos and podcasts

Title
Date
Link

Companies

Company
CEO
Location
Products/Services

News

Title
Author
Date
Publisher
Description
Hoth Therapeutics, Inc.
February 2, 2021
www.prnewswire.com:443
/PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company today is providing shareholders with an update on its pipeline of novel...

References

Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.